Nature Methods publish Application Note - A humanized phenotypic screening platform for chronic pain
Censo Biotechnologies and Cellectricon have joined forces to develop a first-in-kind humanized drug discovery platform to target chronic pain. The platform is based on human induced pluripotent stem cell–derived neurons in combination with Cellectricon's Cellaxess® Elektra screening system.
The combination of highly functional screening with a human cell type of relevance for chronic pain has the potential to enable the generation of better drug candidates for this condition and other diseases.
Physiologically relevant human models of chronic pain are essential for the development of new therapeutics and to overcome poor translation between animal studies and the clinical setting.
In this Application Note, published in Nature Methods as part of the Springer Nature Content Sharing Initiative, we describe how sensory neurons derived from human induced pluripotent stem cells (hiPSCs) with a relevant expression profile can be applied in screening to identify compounds that change a disease phenotype, such as neuronal excitability, rather than the activity of specific targets.
We envision that the described platform could be used in clinical trials in a dish, which could vastly improve the translation of drug candidates in human subjects with chronic pain and other devastating diseases.